Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 4/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19667310 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2USP30RECQLGPR119 | |
| SCHEMBL3276399 | 0.82 | UCHL1 (0.44) | USP2SMN1; SMN2USP30RECQLGPR119 | |
| SCHEMBL17813928 | 0.82 | USP2 (0.43) | USP2SMN1; SMN2USP30RECQLGPR119 | |
| SCHEMBL17813927 | 0.82 | NR1H2 (0.44) | USP2SMN1; SMN2USP30RECQLGPR119 | |
| SCHEMBL3276778 | 0.82 | SMN1; SMN2 (0.50) | USP2SMN1; SMN2MTORUSP30RECQL | |
| SCHEMBL3276273 | 0.80 | UCHL1 (0.49) | USP2SMN1; SMN2USP30GPR119 | |
| SCHEMBL11985662 | 0.77 | MAPK1 (0.57) | USP2SMN1; SMN2USP30GPR119NAMPT | |
| SCHEMBL31046947 | 0.77 | MAPK1 (0.57) | USP2SMN1; SMN2USP30GPR119NAMPT | |
| SCHEMBL17276500 | 0.76 | SMN1; SMN2 (0.62) | USP2SMN1; SMN2RECQLGPR119AKR1C3 | |
| SCHEMBL3276974 | 0.76 | ABHD6 (0.50) | USP2SMN1; SMN2MTORUSP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123644-B1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8247403-B2 | Benzoxazepine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2123644-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | HTR2C, HTR5A, HTR2B | USP2 2256/4885SMN1; SMN2 2200/4885MTOR 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.